Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 15, 2007
[Advances in therapeutic strategies for multiple myeloma]Akiyoshi Miwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 12, 2007
[Bisphosphonates for myeloma patients]Akiyoshi Miwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 12, 2007
[How to diagnose a patient precisely as a myeloma patient?--Lots of problems during diagnostic process]Akiyoshi Miwa
Rare Tumors|January 21, 2016
Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in MyelomaJunichiro Takano, Shotaro Hagiwara, Akiyoshi Miwa
Cureus|July 9, 2024
Blastic Plasmacytoid Dendritic Cell Neoplasm Developed in Chronic Myeloid Leukemia in Molecular Remission During a Four-Year Treatment-Free Interval After Six Years of Dasatinib TreatmentHiroshi Suzuki, Masataka Takeshita, Risen Hirai, et al.
Rinsho Shinkeigaku = Clinical Neurology|July 12, 2008
[Case of primary intraocular central nervous system lymphoma with high interleukin 10 level and positive cytology in cerebrospinal fluid]Takuto Hideyama, Hiroshi Tanaka, Yoshikazu Uesaka, et al.
The Journal of Medical Investigation : JMI|September 18, 2010
Immunohistochemical findings in the pancreatic islets of a patient with transfusional iron overload and diabetes: case reportMiyako Kishimoto, Hisako Endo, Shotaro Hagiwara, et al.
International Journal of Hematology|February 2, 2018
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF aloneAkira Tanimura, Risen Hirai, Miki Nakamura, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|January 16, 2014
Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot studyNaoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 16, 2011
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl]Naohiro Sekiguchi, Naoki Takezako, Mitsuhiro Haga, et al.
Pageof 4